Table of Contents

company-logo

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Aptevo Therapeutics Dividend Announcement

• Aptevo Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Aptevo Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Aptevo Therapeutics Dividend History

Aptevo Therapeutics Dividend Yield

Aptevo Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Aptevo Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Aptevo Therapeutics Financial Ratios

P/E ratio-0.04
PEG ratio-0.00
P/B ratio0.23
ROE-348.75%
Payout ratio-0.03%
Current ratio1.70
Quick ratio1.70
Cash Ratio1.32

Aptevo Therapeutics Dividend FAQ

Does Aptevo Therapeutics stock pay dividends?
Aptevo Therapeutics does not currently pay dividends to its shareholders.
Has Aptevo Therapeutics ever paid a dividend?
No, Aptevo Therapeutics has no a history of paying dividends to its shareholders. Aptevo Therapeutics is not known for its dividend payments.
Why doesn't Aptevo Therapeutics pay dividends?
There are several potential reasons why Aptevo Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Aptevo Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Aptevo Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Aptevo Therapeutics a dividend aristocrat?
Aptevo Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Aptevo Therapeutics a dividend king?
Aptevo Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Aptevo Therapeutics a dividend stock?
No, Aptevo Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Aptevo Therapeutics stocks?
To buy Aptevo Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Aptevo Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.